[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631351":3},{"organization":4,"outcomesModule":7,"designInfo":46,"detailedDescription":16,"studyPopulation":16,"armGroups":52,"interventions":70,"overallOfficials":16,"centralContacts":81,"locations":87,"responsibleParty":160,"collaborators":16,"id":162,"slug":163,"hasResults":164,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":16,"eligibilityCriteria":168,"healthyVolunteers":164,"sex":169,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":16,"studyType":175,"phases":176,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":90,"whyStopped":16,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},{"fullName":5,"class":6},"Huahui Health","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":40},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of participants with HDV RNA below LLOQ with TND or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment period","Proportion of participants with HDV RNA below Lower Limit of Quantification (LLOQ) with target not detected (TND) or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment period","Week 48",[14,18,20,22,24,26,28,30,32,35,37],{"measure":15,"description":16,"timeFrame":17},"Proportion of participants with HDV RNA below LLOQ or a decrease of ≥ 2 log10 from baseline, and ALT normalization",null,"up to week 96",{"measure":19,"description":16,"timeFrame":17},"Proportion of participants with HDV RNA below LLOQ or a decrease of ≥ 2 log10 from baseline",{"measure":21,"description":16,"timeFrame":17},"Proportion of participants with plasma HDV RNA achieving HDV RNA \u003C LLOQ",{"measure":23,"description":16,"timeFrame":17},"Proportion of participants with ALT normalization",{"measure":25,"description":16,"timeFrame":17},"Change from baseline in liver stiffness measurement (LSM)",{"measure":27,"description":16,"timeFrame":17},"Change from baseline in plasma HDV RNA levels at different time points",{"measure":29,"description":16,"timeFrame":17},"Change from baseline in Model for End-Stage Liver Disease (MELD) score at different time points",{"measure":31,"description":16,"timeFrame":17},"Change from baseline in Child-Pugh score at different time points during the treatment period, extended treatment period and follow-up period. (A higher Child-Pugh score indicates poorer liver function, more severe disease, and a worse prognosis)",{"measure":33,"description":16,"timeFrame":34},"Liver related clinical events","up to week 120",{"measure":36,"description":16,"timeFrame":34},"Percentage of participants with treatment-emergent adverse events (TEAEs)",{"measure":38,"description":39,"timeFrame":17},"Ctrough,ss","Steady-state trough concentration of libevitug",[41,44],{"measure":42,"description":16,"timeFrame":43},"HDV and HBV genotyping","baseline",{"measure":45,"description":16,"timeFrame":34},"Change from baseline in quality of life assessed with questionnaire (Hepatitis B quality of life instrument (HBQoL) Version 1.0 and Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) version 4.0 ) at all postbaseline assessments",{"allocation":47,"interventionModel":48,"interventionModelDescription":16,"primaryPurpose":49,"observationalModel":16,"timePerspective":16,"maskingInfo":50},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":51,"maskingDescription":16,"whoMasked":16},"NONE",[53,59,64],{"label":54,"type":55,"description":56,"interventionNames":57},"Libevitug 20 mg\u002Fkg","EXPERIMENTAL","Participants will receive libevitug at a dose of 20 mg\u002Fkg Q2W via intravenous infusion for 96 weeks",[58],"Drug: Libevitug 20 mg\u002Fkg",{"label":60,"type":55,"description":61,"interventionNames":62},"Libevitug 10 mg\u002Fkg","Participants will receive libevitug at a dose of 10 mg\u002Fkg Q2W via intravenous infusion for 96 weeks",[63],"Drug: Libevitug 10 mg\u002Fkg",{"label":65,"type":66,"description":67,"interventionNames":68},"Control group\u002Fdelayed treatment with libevitug 20 mg\u002Fkg","ACTIVE_COMPARATOR","Participants will be observed as comparator for 48 weeks, then to receive libevitug 20 mg\u002Fkg for 48 weeks",[69],"Other: Delayed treatment with libevitug",[71,75,77],{"type":72,"name":54,"description":73,"armGroupLabels":74,"otherNames":16},"DRUG","Route of administration: intravenous infusion",[54],{"type":72,"name":60,"description":73,"armGroupLabels":76,"otherNames":16},[60],{"type":78,"name":79,"description":73,"armGroupLabels":80,"otherNames":16},"OTHER","Delayed treatment with libevitug",[65],[82],{"name":83,"role":84,"phone":85,"phoneExt":16,"email":86},"Jiaying Wen PM","CONTACT","+86 13552466248","wenjiaying@hhhbio.com",[88,102,114,124,133,144,154],{"facility":89,"status":90,"city":91,"state":92,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":16},"Site 201","RECRUITING","Garden Grove","California","92844","United States","US",{"type":97,"coordinates":98},"Point",[99,100],-117.94145,33.77391,{"lat":100,"lon":99},{"facility":103,"status":90,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":16},"Site 101","Changchun","Jilin","130033","China","CN",{"type":97,"coordinates":110},[111,112],125.32278,43.88,{"lat":112,"lon":111},{"facility":115,"status":90,"city":116,"state":117,"zip":118,"country":107,"countryCode":108,"cosmosGeoPoint":119,"geoPoint":123,"contacts":16},"Site 104","Kashgar","Xinjiang Uygur Autonomous Region","844000",{"type":97,"coordinates":120},[121,122],75.98675,39.46718,{"lat":122,"lon":121},{"facility":125,"status":90,"city":126,"state":117,"zip":127,"country":107,"countryCode":108,"cosmosGeoPoint":128,"geoPoint":132,"contacts":16},"Site 103","Ürümqi","830000",{"type":97,"coordinates":129},[130,131],87.60046,43.80096,{"lat":131,"lon":130},{"facility":134,"status":90,"city":135,"state":136,"zip":16,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":16},"Site 303","Rawalpindi","Punjab Province","Pakistan","PK",{"type":97,"coordinates":140},[141,142],73.0479,33.59733,{"lat":142,"lon":141},{"facility":145,"status":90,"city":146,"state":147,"zip":148,"country":137,"countryCode":138,"cosmosGeoPoint":149,"geoPoint":153,"contacts":16},"Site 301","Karachi","Sindh","74800",{"type":97,"coordinates":150},[151,152],67.0104,24.8608,{"lat":152,"lon":151},{"facility":155,"status":90,"city":146,"state":147,"zip":156,"country":137,"countryCode":138,"cosmosGeoPoint":157,"geoPoint":159,"contacts":16},"Site 302","75600",{"type":97,"coordinates":158},[151,152],{"lat":152,"lon":151},{"type":161,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100631351","phase-3-a-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-libevitug-in-participants-with-chronic-hdv-infection-d-clear-study-100631351",false,"NCT07499544","A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)","A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)","Inclusion Criteria:\n\n* Willing to sign written informed consent;\n* Chronic HDV history with at least 6 months;\n* HDV RNA ≥500 IU\u002FmL at screening;\n* ALT \\>1ULN and \\\u003C10×ULN;\n* Able to communicate well and comply with protocol.\n\nExclusion Criteria:\n\n* Concomitant decompensated cirrhosis;\n* Previous or current HCC or suspicion for HCC;\n* Participants with history of alcoholic liver disease, nonalcoholic steatohepatitis or other clinically significant chronic liver diseases not caused by HDV\u002FHBV;\n* Participants with active hepatitis C infection, or HIV infection;\n* Alcohol abuse or drug addiction within 1 year;\n* Participants have participated in other clinical trial within 1 month;\n* Pregnant, lactating women.","ALL","12 Years","70 Years",{"count":173,"type":174},160,"ESTIMATED","INTERVENTIONAL",[177],"PHASE3","This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.",[180],"Chronic Hepatitis D Infection",[182,183],"Hepatitis Delta Virus (HDV)","Viral hepatitis","2026-08-21",{"date":186,"type":187},"2026-08-24","ACTUAL",{"date":189,"type":187},"2026-04-22",{"date":191,"type":174},"2030-01-29",{"name":5,"class":6},7]